These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6282800)

  • 21. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.
    Higashitani F; Hyodo A; Ishida N; Inoue M; Mitsuhashi S
    J Antimicrob Chemother; 1990 Apr; 25(4):567-74. PubMed ID: 2161820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The semi-synthetic thienamycin derivative MK0787 and its properties with respect to a range of beta-lactamases from clinically relevant bacterial species.
    RIchmond MH
    J Antimicrob Chemother; 1981 Mar; 7(3):279-85. PubMed ID: 6974167
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases.
    Gutmann L; Kitzis MD; Yamabe S; Acar JF
    Antimicrob Agents Chemother; 1986 May; 29(5):955-7. PubMed ID: 3015011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In-vitro evaluation of sulbactam, a penicillanic acid sulphone with beta-lactamase inhibitory properties.
    Greenwood D; Eley A
    J Antimicrob Chemother; 1982 Aug; 10(2):117-23. PubMed ID: 6288651
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of clavulanic acid, sulbactam and tazobactam on three different beta-lactamases from Bacteroides uniformis, Clostridium butyricum and Fusobacterium nucleatum.
    Hedberg M; Lindqvist L; Tunér K; Nord CE
    J Antimicrob Chemother; 1992 Jul; 30(1):17-25. PubMed ID: 1331018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 6-(Methoxymethylene)penicillanic acid: inactivator of RTEM beta-lactamase from Escherichia coli.
    Brenner DG; Knowles JR
    Biochemistry; 1984 Nov; 23(24):5839-46. PubMed ID: 6098300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro].
    Blahová J; Hupková M; Krcméry V
    Cas Lek Cesk; 1995 Sep; 134(17):558-61. PubMed ID: 7553760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection, distribution and inhibition of Branhamella catarrhalis beta-lactamases.
    Philippon A; Riou JY; Guibourdenche M; Sotolongo F
    Drugs; 1986; 31 Suppl 3():64-9. PubMed ID: 3015547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives.
    Micetich RG; Maiti SN; Spevak P; Hall TW; Yamabe S; Ishida N; Tanaka M; Yamazaki T; Nakai A; Ogawa K
    J Med Chem; 1987 Aug; 30(8):1469-74. PubMed ID: 3039137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inconsistency of synergy between the beta-lactamase inhibitor CP-45,899 and beta-lactam antibiotics against multiply drug-resistant Enterobacteriaceae and pseudomonas species.
    Fass RJ
    Antimicrob Agents Chemother; 1981 Feb; 19(2):361-3. PubMed ID: 6289732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of beta-lactamase inhibitors in chemotherapy.
    Neu HC
    Pharmacol Ther; 1985; 30(1):1-18. PubMed ID: 3018803
    [No Abstract]   [Full Text] [Related]  

  • 33. Fixed or variable concentrations of beta-lactamase inhibitors in in-vitro tests?
    Greenwood D
    J Antimicrob Chemother; 1996 Jul; 38(1):17-20. PubMed ID: 8858452
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparative in-vitro activities of GD-40 and other beta-lactamase inhibitors against TEM-1 and SHV-2 beta-lactamases.
    Danelon G; Mascaretti O; Radice M; Power P; Calcagno ML; Mata EG; Gutkind G
    J Antimicrob Chemother; 1998 Feb; 41(2):313-5. PubMed ID: 9533481
    [No Abstract]   [Full Text] [Related]  

  • 35. In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors.
    Barry AL; Jones RN; Packer RR
    J Antimicrob Chemother; 1986 Jan; 17(1):125-7. PubMed ID: 3005222
    [No Abstract]   [Full Text] [Related]  

  • 36. 6-Acetylmethylenepenicillanic acid (Ro 15-1903), a potent beta-lactamase inhibitor. I. Inhibition of chromosomally and R-factor-mediated beta-lactamases.
    Arisawa M; Then RL
    J Antibiot (Tokyo); 1982 Nov; 35(11):1578-83. PubMed ID: 6298167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA; Rudin SA; Shlaes DM
    FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Penicillanic acid sulfone: nature of irreversible inactivation of RTEM beta-lactamase from Escherichia coli.
    Brenner DG; Knowles JR
    Biochemistry; 1984 Nov; 23(24):5833-9. PubMed ID: 6098299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.
    Campoli-Richards DM; Brogden RN
    Drugs; 1987 Jun; 33(6):577-609. PubMed ID: 3038500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Beta-lactamase producers and other bacteria: which ones to take into consideration and when? The concept of beta-lactamase inhibitor].
    Jarlier V
    Presse Med; 1998 Sep; 27 Suppl 4():17-8. PubMed ID: 9798480
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.